Wave Life Sciences Ltd. (WVE)

Wave Life Sciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	108.3	113.31	3.65	40.96	20.08
Revenue Growth (YoY)	-4.42%	3005.10%	-91.09%	104.03%	25.61%
Cost of Revenue	159.68	130.01	115.86	121.88	130.94
Gross Profit	-51.38	-16.7	-112.21	-80.91	-110.87
Selling, General & Admin	59.02	51.29	50.51	46.11	42.51
Operating Expenses	59.02	51.29	50.51	46.11	42.51
Operating Income	-110.4	-68	-162.72	-127.02	-153.38
Interest & Investment Income	10.16	7.93	1.57	0.03	0.57
Other Non Operating Income (Expenses)	3.23	1.88	0.01	4.54	2.06
Pretax Income	-97.01	-58.19	-161.14	-122.45	-150.75
Income Tax Expense	-	-0.68	0.68	-0.2	-0.84
Net Income	-97.01	-57.51	-161.82	-122.25	-149.91
Net Income to Common	-97.01	-57.51	-161.82	-122.25	-149.91
Shares Outstanding (Basic)	138	106	79	52	39
Shares Outstanding (Diluted)	138	106	79	52	39
Shares Change (YoY)	30.33%	34.55%	52.16%	32.12%	15.83%
EPS (Basic)	-0.70	-0.54	-2.05	-2.36	-3.82
EPS (Diluted)	-0.70	-0.54	-2.05	-2.36	-3.82
Free Cash Flow	-151.96	-20.55	-129.14	-89.55	-117.32
Free Cash Flow Per Share	-1.10	-0.19	-1.64	-1.73	-2.99
Gross Margin	-47.44%	-14.74%	-	-197.52%	-
Operating Margin	-101.94%	-60.01%	-4459.30%	-310.07%	-763.94%
Profit Margin	-89.57%	-50.76%	-4434.72%	-298.42%	-746.68%
Free Cash Flow Margin	-140.31%	-18.13%	-3539.11%	-218.61%	-584.35%
EBITDA	-106.51	-63	-156.15	-119.53	-145.26
EBITDA Margin	-98.34%	-55.60%	-	-291.80%	-
D&A For EBITDA	3.9	5	6.57	7.48	8.11
EBIT	-110.4	-68	-162.72	-127.02	-153.38
EBIT Margin	-101.94%	-60.01%	-	-	-

Updated Mar 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q